HeyJaredAmina Niasse
- Indexed articles, last 90 days
- 8
- Latest publication
- Sep 17, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 8, 2026
Latest articles
CVS Health's Aetna to Streamline Cancer Treatment Approvals (opens the original)
Read excerpt
NEW YORK, Sept 17 (Reuters) - CVS Health's Aetna health insurance unit will cut back next year on the preapprovals it requires for treatment for cancer patients to only one medical prior authorization process early on, the company said on Thursday. Providers will get the insurer's go-ahead for care by submitting documentation showing a patient is receiving treatment for cancer rather than submitting separate approvals for its various components such as chemotherapy, radiation treatment, imagi
GoodRx offers health subscription for families, to launch as employee benefit in 2027 (opens the original)
Read excerpt
NEW YORK, Sept 3 (Reuters) - GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and over 250 medications, and it plans to launch the program as part of employer health benefits in 2027. The program, called Companion, offers 250 generic medications for free and discounted access to telehealth, vision, dental and lab services for families paying $24.99 each month. The subscription was previously only available d
More US Employers to Drop Weight-loss Drugs in 2027, as Healthcare Costs Increase (opens the original)
Read excerpt
NEW YORK, Aug 25 (Reuters) - About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs, according to a survey released on Tuesday by the Business Group on Health. Healthcare costs are set to increase 9.2% if employers do not make changes to manage costs in 2027, up from 8.5% in 2026, the group said. Two-thirds of employers surveyed said they saw rising utilization of the drugs. GLP-1 weight-loss drugs, such as Novo
More US employers to drop weight-loss drugs in 2027, as healthcare costs increase (opens the original)
Read excerpt
NEW YORK, Aug 25 (Reuters) - About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs, according to a survey released on Tuesday by the Business Group on Health. Healthcare costs are set to increase 9.2% if employers do not make changes to manage costs in 2027, up from 8.5% in 2026, the group said. Two-thirds of employers surveyed said they saw rising utilization of the drugs. GLP-1 weight-loss drugs, such as Novo N
As Hims prepares for peptides launch, Wall Street cautious on prospects this year (opens the original)
Read excerpt
NEW YORK, Aug 12 (Reuters) - Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's quarterly results this week said sales for that offering are unlikely to drive revenue growth this year. Peptide treatments, built from short chains of amino acids, have become a healthcare rage, despite lacking FDA approval. Some of the treatments, used for everything from anti-aging to muscle recovery, are avail
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.